Table 1.
Characteristics of the trials (n = 106), reporting of comorbidity, and exclusion based on comorbidity
| No. of studies (%) | |
|---|---|
| Mean age in years (range)a | 67.6 (37.2–80.4) |
| Proportion of male subjectsa | 66.7 |
| Chronic heart failure | 98 (92) |
| Type of intervention | |
| Drug intervention | 31 (29) |
| Non-drug intervention (e.g. surgery, exercise and dietary interventions) | 48 (45) |
| Health service intervention (e.g. nurse-led (tele)monitoring, multidisciplinary monitoring, education on CHF management) | 27 (26) |
| Sample size median (IQR) | 111 (46–265) |
| NYHA classification used in inclusion | |
| Only I–II | 3 (3) |
| Only II–III | 22 (21) |
| Only III–IV | 5 (5) |
| All | 76 (72) |
| Excluded conditions | |
| Diabetes mellitus | 12 (11) |
| Hypertension | 10 (9) |
| Other cardiovascular disease including dyslipidaemia | 71 (67) |
| Other non-cardiovascular disease | 72 (68) |
| Type of conditions reported | |
| Diabetes mellitus | 63 (59) |
| Hypertension | 58 (55) |
| Other cardiovascular disease including dyslipidaemia | 58 (55) |
| Other non-cardiovascular disease | 42 (40) |
aCalculated over all studies